Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance
Acute myeloid leukemia (AML) is a heterogeneous disease with variable patient responses to therapy. Selinexor, an inhibitor of nuclear export, has shown promising clinical activity for AML. To identify the molecular context for monotherapy sensitivity as well as rational drug combinations, we profil...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 9, 2022
|
| In: |
Cell reports
Year: 2022, Jahrgang: 40, Heft: 6, Pages: 1-18, e1-e6 |
| ISSN: | 2211-1247 |
| DOI: | 10.1016/j.celrep.2022.111177 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.celrep.2022.111177 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2211124722009901 
|
| Verfasserangaben: | Kristina B. Emdal, Nicolàs Palacio-Escat, Caroline Wigerup, Akihiro Eguchi, Helén Nilsson, Dorte B. Bekker-Jensen, Lars Rönnstrand, Julhash U. Kazi, Alexandre Puissant, Raphaël Itzykson, Julio Saez-Rodriguez, Kristina Masson, Peter Blume-Jensen, and Jesper V. Olsen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1832565327 | ||
| 003 | DE-627 | ||
| 005 | 20230707000132.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230127s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2022.111177 |2 doi | |
| 035 | |a (DE-627)1832565327 | ||
| 035 | |a (DE-599)KXP1832565327 | ||
| 035 | |a (OCoLC)1389536071 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Emdal, Kristina B. |e VerfasserIn |0 (DE-588)1279316241 |0 (DE-627)1832566749 |4 aut | |
| 245 | 1 | 0 | |a Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance |c Kristina B. Emdal, Nicolàs Palacio-Escat, Caroline Wigerup, Akihiro Eguchi, Helén Nilsson, Dorte B. Bekker-Jensen, Lars Rönnstrand, Julhash U. Kazi, Alexandre Puissant, Raphaël Itzykson, Julio Saez-Rodriguez, Kristina Masson, Peter Blume-Jensen, and Jesper V. Olsen |
| 264 | 1 | |c August 9, 2022 | |
| 300 | |a 24 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.01.2023 | ||
| 520 | |a Acute myeloid leukemia (AML) is a heterogeneous disease with variable patient responses to therapy. Selinexor, an inhibitor of nuclear export, has shown promising clinical activity for AML. To identify the molecular context for monotherapy sensitivity as well as rational drug combinations, we profile selinexor signaling responses using phosphoproteomics in primary AML patient samples and cell lines. Functional phosphosite scoring reveals that p53 function is required for selinexor sensitivity consistent with enhanced efficacy of selinexor in combination with the MDM2 inhibitor nutlin-3a. Moreover, combining selinexor with the AKT inhibitor MK-2206 overcomes dysregulated AKT-FOXO3 signaling in resistant cells, resulting in synergistic anti-proliferative effects. Using high-throughput spatial proteomics to profile subcellular compartments, we measure global proteome and phospho-proteome dynamics, providing direct evidence of nuclear translocation of FOXO3 upon combination treatment. Our data demonstrate the potential of phosphoproteomics and functional phosphorylation site scoring to successfully pinpoint key targetable signaling hubs for rational drug combinations. | ||
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a combination therapy | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a functional scoring | |
| 650 | 4 | |a mass spectrometry | |
| 650 | 4 | |a MK-2206 | |
| 650 | 4 | |a nutlin-3a | |
| 650 | 4 | |a phosphoproteomics | |
| 650 | 4 | |a selinexor | |
| 650 | 4 | |a subcellular proteomics | |
| 700 | 1 | |a Palacio-Escat, Nicolàs |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wigerup, Caroline |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eguchi, Akihiro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nilsson, Helén |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bekker-Jensen, Dorte B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rönnstrand, Lars |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kazi, Julhash U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Puissant, Alexandre |e VerfasserIn |4 aut | |
| 700 | 1 | |a Itzykson, Raphaël |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sáez Rodríguez, Julio |d 1978- |e VerfasserIn |0 (DE-588)133764362 |0 (DE-627)555766632 |0 (DE-576)300083114 |4 aut | |
| 700 | 1 | |a Masson, Kristina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blume-Jensen, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Olsen, Jesper V. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d Maryland Heights, MO : Cell Press, 2012 |g 40(2022), 6 vom: 9. Aug., Artikel-ID 111177, Seite 1-18, e1-e6 |h Online-Ressource |w (DE-627)684964562 |w (DE-600)2649101-1 |w (DE-576)358411572 |x 2211-1247 |7 nnas |a Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:6 |g day:9 |g month:08 |g elocationid:111177 |g pages:1-18, e1-e6 |g extent:24 |a Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.celrep.2022.111177 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2211124722009901 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230127 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 133764362 |a Sáez Rodríguez, Julio |m 133764362:Sáez Rodríguez, Julio |d 910000 |d 912900 |e 910000PS133764362 |e 912900PS133764362 |k 0/910000/ |k 1/910000/912900/ |p 11 | ||
| 999 | |a KXP-PPN1832565327 |e 4252376971 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"August 9, 2022","dateIssuedKey":"2022"}],"name":{"displayForm":["Kristina B. Emdal, Nicolàs Palacio-Escat, Caroline Wigerup, Akihiro Eguchi, Helén Nilsson, Dorte B. Bekker-Jensen, Lars Rönnstrand, Julhash U. Kazi, Alexandre Puissant, Raphaël Itzykson, Julio Saez-Rodriguez, Kristina Masson, Peter Blume-Jensen, and Jesper V. Olsen"]},"recId":"1832565327","id":{"doi":["10.1016/j.celrep.2022.111177"],"eki":["1832565327"]},"physDesc":[{"extent":"24 S."}],"language":["eng"],"note":["Gesehen am 27.01.2023"],"title":[{"title":"Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance","title_sort":"Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance"}],"relHost":[{"title":[{"title":"Cell reports","title_sort":"Cell reports"}],"language":["eng"],"disp":"Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistanceCell reports","id":{"eki":["684964562"],"zdb":["2649101-1"],"issn":["2211-1247"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"684964562","type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"volume":"40","extent":"24","text":"40(2022), 6 vom: 9. Aug., Artikel-ID 111177, Seite 1-18, e1-e6","pages":"1-18, e1-e6","issue":"6","year":"2022"},"pubHistory":["1.2012 -"],"origin":[{"publisher":"Cell Press ; Elsevier","dateIssuedKey":"2012","publisherPlace":"Maryland Heights, MO ; [New York, NY]","dateIssuedDisp":"2012-"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"Kristina B.","roleDisplay":"VerfasserIn","role":"aut","display":"Emdal, Kristina B.","family":"Emdal"},{"family":"Palacio-Escat","display":"Palacio-Escat, Nicolàs","roleDisplay":"VerfasserIn","role":"aut","given":"Nicolàs"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Caroline","family":"Wigerup","display":"Wigerup, Caroline"},{"display":"Eguchi, Akihiro","family":"Eguchi","given":"Akihiro","role":"aut","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Helén","family":"Nilsson","display":"Nilsson, Helén"},{"given":"Dorte B.","roleDisplay":"VerfasserIn","role":"aut","display":"Bekker-Jensen, Dorte B.","family":"Bekker-Jensen"},{"given":"Lars","roleDisplay":"VerfasserIn","role":"aut","display":"Rönnstrand, Lars","family":"Rönnstrand"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Julhash U.","family":"Kazi","display":"Kazi, Julhash U."},{"given":"Alexandre","role":"aut","roleDisplay":"VerfasserIn","display":"Puissant, Alexandre","family":"Puissant"},{"given":"Raphaël","roleDisplay":"VerfasserIn","role":"aut","display":"Itzykson, Raphaël","family":"Itzykson"},{"given":"Julio","roleDisplay":"VerfasserIn","role":"aut","display":"Sáez Rodríguez, Julio","family":"Sáez Rodríguez"},{"family":"Masson","display":"Masson, Kristina","role":"aut","roleDisplay":"VerfasserIn","given":"Kristina"},{"display":"Blume-Jensen, Peter","family":"Blume-Jensen","given":"Peter","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Olsen, Jesper V.","family":"Olsen","given":"Jesper V.","roleDisplay":"VerfasserIn","role":"aut"}]} | ||
| SRT | |a EMDALKRISTPHOSPHOPRO9202 | ||